CCN2 and systemic sclerosis: Another study found that IGFBP-4 has an antifibrotic role in systemic sclerosis, a prototypic fibrotic disorder [33], through reducing TGFβ-induced ECM production and the expression of the profibrotic factor CTGF [33].